Table 3.
Training and validation cohort for nomogram to predict 5- and 8-year cancer-specific survival rates of low-grade brainstem glioma patient.
| Training n (%) | Validation n (%) | P | |
|---|---|---|---|
| Age | 1.000 | ||
| ≥22 Adult | 70 (23.0) | 70 (23.0) | |
| <22 Pediatric | 82 (26.9) | 83 (27.1) | |
| Sex | 0.448 | ||
| Female | 62 (20.3) | 70 (23.0) | |
| Male | 90 (29.5) | 83 (27.2) | |
| Race | 0.199 | ||
| White | 126 (41.3) | 135 (44.3) | |
| Black | 14 (4.6) | 13 (4.3) | |
| Asian or Pacific Islander | 12 (3.9) | 5 (1.6) | |
| Marital status | 0.417 | ||
| Unmarried | 108 (35.4) | 116 (38.0) | |
| Married | 44 (14.4) | 37 (12.2) | |
| WHO grade | 0.272 | ||
| I | 63 (20.7) | 74 (24.3) | |
| II | 89 (29.2) | 79 (25.8) | |
| Surgery | 0.399 | ||
| Local excision/biopsy | 34 (11.2) | 26 (8.5) | |
| STR | 29 (9.5) | 36 (11.8) | |
| GTR | 89 (29.2) | 91 (29.8) | |
| Size | 0.862 | ||
| ≤ 3.6 cm | 80 (26.2) | 78 (25.6) | |
| >3.6 cm | 72 (23.6) | 75 (24.6) | |
| Metastasis | 0.287 | ||
| No | 150 (49.2) | 147 (48.2) | |
| Yes | 2 (0.6) | 6 (2.0) | |
| Adjuvant therapy | 0.920 | ||
| No/unknown | 83 (27.2) | 79 (25.9) | |
| Both | 9 (3.0) | 9 (3.0) | |
| Radiotherapy | 49 (16.0) | 51 (16.7) | |
| Chemotherapy | 11 (3.6) | 14 (4.6) | |
| Extension | 0.731 | ||
| Brainstem | 61 (22.0) | 59 (19.3) | |
| Cerebellum | 14 (4.6) | 11 (3.6) | |
| Ventricular | 53 (17.4) | 52 (17.0) | |
| Other | 24 (7.9) | 31 (10.2) | |
| Cancer-specific death event | 1 | ||
| Alive | 138 (45.3) | 138 (45.2) | |
| Dead | 14 (4.6) | 15 (4.9) | |
| Vital status | 0.595 | ||
| Alive | 130 (42.6) | 135 (44.3) | |
| Dead | 22 (7.2) | 18 (5.9) |